Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Neothetics NEOT

Healthcare Biotechnology
"Neothetics Inc is a clinical-stage pharmaceutical company developing therapeutics for the aesthetic market. Its product is a novel injectable treatment for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients."

Recent & Breaking News (NDAQ:NEOT)

Neothetics to Present in the 27th Annual Piper Jaffray Healthcare Conference

GlobeNewswire November 24, 2015

Neothetics Reports Third Quarter 2015 Financial Results

GlobeNewswire November 12, 2015

Neothetics to Release Third Quarter 2015 Financial Results

GlobeNewswire November 5, 2015

Neothetics Announces Issuance by USPTO of Additional Patent Directed to LIPO-202 Lead Clinical Asset

GlobeNewswire October 6, 2015

Neothetics Initiates Study to Evaluate the Safety of LIPO-202 for Body Contouring in Obese Subjects

GlobeNewswire September 30, 2015

Neothetics Expands Its Board of Directors With Appointments of Jeffrey Nugent and Hani Zeini

GlobeNewswire September 28, 2015

Neothetics to Present at the OC Summit on Aesthetics and Dermatology

GlobeNewswire September 21, 2015

Neothetics Announces Last Patient Enrolled in LIPO-202 Pivotal Phase 3 Clinical Trials for Reduction of Subcutaneous Abdominal Fat

GlobeNewswire September 8, 2015

Neothetics Reports Second Quarter 2015 Financial Results

GlobeNewswire August 13, 2015

Neothetics Announces Reaffirmation of Patents and Termination of Reexamination Challenge by United States Patent and Trademark Office

GlobeNewswire August 6, 2015

Neothetics Announces Reaffirmation of Patents and Termination of Reexamination Challenge by United States Patent and Trademark Office

GlobeNewswire August 6, 2015

Neothetics to Release Second Quarter 2015 Financial Results

GlobeNewswire August 6, 2015

Neothetics to Release Second Quarter 2015 Financial Results

GlobeNewswire August 6, 2015

Neothetics Initiates Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202 for Body Contouring

GlobeNewswire June 30, 2015

Neothetics Reports First Quarter 2015 Financial Results

GlobeNewswire May 14, 2015

Neothetics to Release First Quarter 2015 Financial Results, Host Annual Stockholder Meeting

GlobeNewswire May 7, 2015

Neothetics Initiates Pivotal Phase 3 Clinical Trials for LIPO-202, the First Non-Invasive Injectable Drug Candidate for Reduction of Subcutaneous Abdominal Fat

GlobeNewswire April 13, 2015

Neothetics to Present at Needham & Company's 14th Annual Healthcare Conference

GlobeNewswire April 8, 2015

Neothetics Reports Fourth Quarter and Full Year 2014 Financial Results

GlobeNewswire March 26, 2015

Neothetics Initiates Study to Evaluate Safety of Retreatment With LIPO-202 for Body Contouring

GlobeNewswire March 23, 2015